Investor Announcements - 2012


EKF announces 2012 Interim Results.

EKF Diagnostics announces that subsidiaries of EKF have entered into a Settlement Agreement with HemoCue AB and HemoCue Inc in relation to patent-related litigation in Germany and the US. 

EKF Diagnostics announces that it has signed an exclusive license agreement with the Joslin Diabetes Center (“Joslin”).

EKF Diagnostics announces that it has sold its Swiss subsidiary, International Brand Licensing AG for a cash consideration of £50,000, payable over a two year period. 

EKF Diagnostics announces its audited final results for the year ended 31 December 2011, a year of continued progress.